Who is sponsoring NCT05040529?

NCT05040529 is sponsored by Gangnam Severance Hospital.

What drugs are being tested in NCT05040529?

Interventions in NCT05040529: pure laparoscopic donor hepatectomy, conventional open donor hepatectomy.

What condition does NCT05040529 study?

NCT05040529 studies Healthy Donors for Liver Transplantation.

Is NCT05040529 still recruiting?

NCT05040529 is currently status unknown. Last updated 10 September 2021.

Last reviewed 2021-09-10 · How we verify

NCT05040529

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Comparison Between Pure Laparoscopic Donor Right Hepatectomy and Convensional Donor Right Hepatectomy

Status unknown Last updated 10 September 2021

What this trial tests

trial testing pure laparoscopic donor hepatectomy in Healthy Donors for Liver Transplantation in 100 participants. Status unknown.

Timeline

1 March 2009

Primary endpoint
28 February 2021

28 March 2022

Quick facts

Lead sponsor	Gangnam Severance Hospital
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	100
Start date	1 March 2009
Primary completion	28 February 2021
Estimated completion	28 March 2022
Sites	1 location across South Korea

Drugs / interventions tested

pure laparoscopic donor hepatectomy
conventional open donor hepatectomy

Conditions studied

Healthy Donors for Liver Transplantation — all drugs for Healthy Donors for Liver Transplantation →

Sponsor

Gangnam Severance Hospital

Who can join

Adults 17 to 65, any sex, with Healthy Donors for Liver Transplantation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Perioperative clincal outcome between PLDRH and conventional open donor right hepatectomy (ODRH) will be compared retrospectively.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Gangnam Severance Hospital trials

Trials by the same sponsor.

NCT07505628 — AI-based Rehabilitation for Hip and Knee Surgery Patients · NA · not yet recruiting
NCT07311122 — Endocrine Therapy Base on 21-gene RS · not yet recruiting
NCT07011823 — Immune-checkpoint Blockade After Partial Breast Irradiation by Pembrolizumab in Early TNBC · Phase 2 · not yet recruiting
NCT07211451 — Axillary Nodal Burden in HER2+ and TNBC · completed
NCT06839716 — Comparison of Ropivacaine-Poloxamer 407 Hydrogel and TAP Block for Postoperative Pain Management in Laparoscopic/Robotic · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05040529 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Gangnam Severance Hospital
Last refreshed: 10 September 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05040529.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing